Clinical Trial Update: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether the CagriSema combination (cagrilintide plus semaglutide) can reduce kidney damage in people with chronic kidney disease and typ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)
• Cagrilintide (cagrilintide)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Status: COMPLETED